[Home](https://github.com/mm80843/T3.5/blob/main/docs/index.md) >> Class: [Benef](https://github.com/mm80843/T3.5/tree/main/docs/Benef/index.md) >> Individual ID:PBN__Benef_752 

# __Reduction in aerosol transmission__

## Name of the Benefit

Air filtration devices reduce the likelihood of airborne transmission of SARS-CoV-2, protecting both patients and healthcare workers from infection.

## Description of actual returns pertaining to this benefit

* [Private investors benefit from reduced transmission rates, a healthier and more confident population, and potential increase in asset values.](https://github.com/mm80843/T3.5/blob/main/docs/BenefReturn/PBN__BenefReturn_817.md)
* [Private investors would benefit from investing in air filtration devices as it would improve patient safety and reduce healthcare costs associated with infections.](https://github.com/mm80843/T3.5/blob/main/docs/BenefReturn/PBN__BenefReturn_1253.md)

## Articles mentionning this Benefit

* [Designing for COVID-2x: Reflecting on Future-Proofing Human Habitation for the Inevitable Next Pandemic](https://github.com/mm80843/T3.5/blob/main/docs/Article/PBN__Article_149.md)
* [The removal of airborne SARS-CoV-2 and other microbial bioaerosols by air filtration on COVID-19 surge units](https://github.com/mm80843/T3.5/blob/main/docs/Article/PBN__Article_232.md)

## Stakeholders benefitting from this Benefit

* [healthcare workers](https://github.com/mm80843/T3.5/blob/main/docs/Stakeholder/PBN__Stakeholder_68.md)
* [patients](https://github.com/mm80843/T3.5/blob/main/docs/Stakeholder/PBN__Stakeholder_31.md)
* [building occupants](https://github.com/mm80843/T3.5/blob/main/docs/Stakeholder/PBN__Stakeholder_97.md)

## Risks which can benefit from this action

* [Improved ventilation systems](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_84.md)
* [Air filtration and UV light sterilisation](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_1130.md)

